Boomerang Medical Awarded “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” by the Crohn’s & Colitis Foundation

Boomerang Medical Awarded “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” by the Crohn’s & Colitis Foundation




Boomerang Medical Awarded “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” by the Crohn’s & Colitis Foundation

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn’s & Colitis Foundation. This award, given for the first time to a medical device company, acknowledges Boomerang Medical’s alignment with the Foundation’s mission to improve the lives of those affected by inflammatory bowel disease.




The Crohn’s & Colitis Foundation is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn’s disease and ulcerative colitis, and to improving the quality of life of children and adults affected by these diseases, which are collectively referred to as inflammatory bowel disease (IBD). The award was presented at the Foundation’s annual President’s Corporate Circle reception, held during the annual Crohn’s & Colitis Congress® on January 26, 2024. This event gathered healthcare professionals and industry leaders, providing a platform to acknowledge significant contributions in the field.

Heather Simonsen, CEO of Boomerang Medical, commented on the significance of this recognition: “We are deeply honored to be acknowledged by the Crohn’s & Colitis Foundation with this award. It reflects our shared commitment to making a tangible difference in the lives of those affected by IBD.”

Boomerang Medical’s collaboration with the Crohn’s & Colitis Foundation has been essential in incorporating the patient perspective into the company’s IBD research. This collaboration has led to the creation of patient advisory panels, a critical initiative that places the patient voice at the forefront of Boomerang Medical’s clinical study designs. These efforts ensure that the company’s research is informed by those most affected by IBD and align with the healthcare industry’s broader movement recognizing the value of patient input in shaping effective and relevant clinical trials.

About the Crohn’s & Colitis Foundation:

The mission of the Crohn’s & Colitis Foundation is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation sponsors basic and clinical research of the highest quality. We also offer a wide range of educational programs for patients and healthcare professionals, while providing supportive services to help people cope with these chronic intestinal diseases. These programs are supported solely through our donors, grants, fundraising efforts, and sponsors. For more information, visit www.crohnscolitisfoundation.org.

About Boomerang Medical, Inc.

Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA for the treatment of Crohn’s disease and ulcerative colitis. Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry. Current investors in the company include Arboretum Ventures and Hatteras Venture Partners. For more information, visit www.boomerangmedical.com.

Contacts

Braden R. Koch

info@boomerangmedical.com